Combined Screening with NIPT (Immulite).

Combined Screening with NIPT (Immulite)

Test Overview

Combined Screening with NIPT (Non-Invasive Prenatal Testing) using the Immulite platform is an advanced prenatal screening test performed during pregnancy to assess the risk of chromosomal abnormalities in the baby. It combines maternal serum marker analysis with highly accurate NIPT technology for enhanced screening performance.

Parameters Included

• Pregnancy-associated plasma protein A (PAPP-A)
• Free Beta hCG
• Maternal age assessment
• Ultrasound findings (NT scan, if applicable)
• Cell-free fetal DNA analysis (NIPT)

Why This Test is Done

• Early detection of chromosomal abnormalities
• Screening for:
  • Down Syndrome (Trisomy 21)
  • Edwards Syndrome (Trisomy 18)
  • Patau Syndrome (Trisomy 13)
• Helps assess fetal genetic health non-invasively
• Supports informed pregnancy management decisions

Sample Required

• Maternal blood sample (Serum / EDTA blood as advised)

Preparation

• No fasting required
• Recommended during the first trimester as advised by the doctor

Reporting Time

• Typically 5–10 working days

Key Benefits

• Non-invasive and safe for both mother and baby
• High sensitivity and accuracy
• Early risk assessment during pregnancy
• Helps reduce unnecessary invasive procedures

Recommended For

• Pregnant women during the first trimester
• Women with advanced maternal age
• Previous history of chromosomal abnormalities
• High-risk pregnancy cases